Making a new medicine is one of the longest, most expensive processes in modern science. From the first spark of an idea to a pill on a pharmacy shelf, the journey typically takes over a decade and costs a median of $708 million per drug, with some estimates reaching $1.31 billion when factoring in the many candidates that fail along the way. The process moves through distinct stages: discovering a target, designing a compound, testing it in labs and then in people, winning regulatory approval, and finally manufacturing it at scale.
Finding a Disease Target
Every medicine starts with a biological question: what’s going wrong in the body, and where can we intervene? Scientists use tools like gene expression data, protein analysis, and genetic association studies to identify a specific molecule or pathway involved in a disease. This could be a protein that helps cancer cells grow, an enzyme that raises blood pressure, or a receptor that triggers inflammation.
Once a target is identified, researchers have to prove it actually matters. They test it using cell-based experiments, animal models, and sometimes by observing what happens when the target is blocked in patients with the disease. If shutting down or activating that target changes the course of the disease, it’s considered validated, and the search for a drug that can do the same thing begins.
Designing and Optimizing a Drug Candidate
With a validated target in hand, researchers screen thousands or even millions of chemical compounds to find ones that interact with it. These early hits are rarely good enough to become medicines on their own. They might bind to the target weakly, break down too quickly in the body, or cause unwanted effects on other systems.
The optimization phase is where chemists systematically tweak the molecular structure of promising compounds. The goal is to make the drug more potent against its target, more selective (so it doesn’t interfere with things it shouldn’t), and better suited to survive the trip through your digestive system and bloodstream. This back-and-forth process of designing, testing, and redesigning can take years before a single candidate is ready for testing in people.
Testing in Clinical Trials
Before any human testing begins, the candidate drug goes through extensive lab and animal studies to establish basic safety. If those results are promising, the company files an application to begin clinical trials, which unfold in three phases.
Phase 1 enrolls 20 to 100 participants, often healthy volunteers. The primary goal is safety: researchers carefully increase the dose to learn how much the body can tolerate, how the drug is absorbed and processed, and what side effects appear at different levels.
Phase 2 expands to up to several hundred patients who actually have the disease being targeted. These studies start generating data on whether the drug works, while continuing to collect safety information. Phase 2 trials aren’t large enough to prove a drug is effective, but they help researchers figure out the right dose and design the larger studies that follow.
Phase 3 is where the real proof happens. These pivotal studies enroll 300 to 3,000 patients and are designed to demonstrate whether the drug provides a genuine treatment benefit. Because these trials are larger and run longer, they’re also more likely to catch rare or long-term side effects that smaller studies missed. Most of a drug’s safety profile comes from Phase 3 data. The majority of drug candidates that enter clinical trials never make it through all three phases.
Winning Regulatory Approval
If a drug clears all three trial phases, its maker submits a New Drug Application to the FDA (or equivalent agencies in other countries). This document tells the drug’s complete story: clinical trial results, animal study data, a full list of ingredients, how the drug behaves in the body, and detailed descriptions of how it will be manufactured, processed, and packaged.
FDA reviewers evaluate three core questions. Is the drug safe and effective for its intended use, and do the benefits outweigh the risks? Is the proposed label (the information sheet that comes with every prescription) accurate and complete? And are the manufacturing methods reliable enough to ensure every batch has the correct identity, strength, quality, and purity? Only after all three questions are satisfied does the drug receive approval.
How Small-Molecule Drugs Are Manufactured
Most traditional medicines, things like ibuprofen, statins, or blood pressure pills, are small molecules built through chemical synthesis. Manufacturing these drugs means running a sequence of chemical reactions that assemble the active ingredient step by step from simpler raw materials. Each reaction transforms the molecule, adding or removing specific atoms to arrive at the final structure.
After each step, the product has to be separated from leftover starting materials, byproducts, and solvents. Purification is one of the most expensive parts of pharmaceutical manufacturing. Techniques range from filtration and distillation to more advanced methods like membrane absorption and simulated moving bed adsorbers. The final active ingredient is then combined with inactive ingredients (fillers, binders, coatings) to create the tablet, capsule, or liquid form you get at the pharmacy.
How Biologics Are Produced
Biologics, a newer class of medicines that includes insulin, monoclonal antibodies, and many cancer therapies, are fundamentally different. Instead of being assembled through chemical reactions, they’re grown inside living cells.
The process starts by engineering a cell line (usually derived from mammalian cells) to produce the desired protein. Once a high-performing cell line is identified, manufacturers create a tiered banking system: a master cell bank of 100 to 300 frozen vials, and working cell banks derived from those. This ensures a consistent starting point for every future production run.
Those cells are then grown in large stainless-steel bioreactors that maintain precise control over temperature, pH, and oxygen levels. Production can run in different modes. In batch culture, cells grow in a fixed volume of nutrients. Fed-batch culture starts the same way but adds concentrated nutrient solutions as supplies run low, extending the production window. Perfusion culture is continuous: spent media is constantly drained and replaced while the cells are retained inside the reactor, allowing longer and more productive runs.
Once the cells have produced enough protein, the harvesting begins. Cells and debris are removed through centrifugation and filtration. The target protein is then captured, purified to remove bulk impurities, and polished to eliminate trace contaminants. This downstream processing has to be extraordinarily precise because even small differences in how a biologic is made can change how it behaves in the body. As regulators often put it: for biologics, the process is the product.
Scaling Up to Commercial Production
A drug that works perfectly in a small lab batch doesn’t automatically work at factory scale. Scaling up is one of the most technically challenging steps in the entire process, particularly for biologics, where any change in manufacturing can alter the final molecule’s safety or effectiveness.
A common rule of thumb suggests batch sizes can be increased tenfold without major problems, but this doesn’t hold universally. Raw material quality can shift between suppliers. Heat and mixing behave differently in a 10,000-liter tank than in a 10-liter flask. Equipment changes, facility transfers, and even something as simple as switching a filter type can introduce subtle variations. Companies run comparability studies at each scale increase to verify that the larger batches match the smaller ones in every meaningful way.
All commercial drug manufacturing must follow Current Good Manufacturing Practice regulations set by the FDA. These rules cover every detail of the process: the facilities, the equipment, the methods, and the quality controls. The goal is to ensure that every pill, vial, or syringe a patient receives is safe, contains exactly what the label says, and is as pure and potent as the version that was tested in clinical trials.
Monitoring After the Drug Reaches Patients
Approval isn’t the end of the story. Phase 4 studies are post-marketing requirements that the FDA can impose as a condition of approval. These studies monitor the drug’s performance in the real world, where it’s used by far more people and in more varied circumstances than any clinical trial could capture.
Some Phase 4 studies focus on specific safety concerns, tracking a particular side effect in a defined group of patients. Others cast a wider net, conducting general surveillance for any adverse reactions that weren’t detected in earlier trials. The FDA also requires studies in populations that are often underrepresented in clinical trials: children, infants, neonates, elderly patients, pregnant women, and specific racial or ethnic groups. These studies help fill in the gaps, revealing how a drug performs across the full range of people who will actually take it.